GGrantIndex
Sort

51,593 grants matching hepatitis

Defining the therapeutic efficacy, tolerogenic potential, and genotoxicity of liver-targeted AAV gene therapy for hemophilia A

$707,639
Graca Duarte Almeida-Porada · Wake Forest University Health Sciences · R01 · FY2022 · HL

The Transitional Liver Clinic (TLC): Reducing Liver Disease Readmission

$707,588
Eric Orman · Indiana University Indianapolis · R01 · FY2023 · DK

Probing the specificity and activity of the metazoan Integrator complex

$707,558
Karen L Adelman · Harvard Medical School · R01 · FY2024 · GM

CVD in American Indians Biomarker lab and Arizona Field Center

$707,555
Barbara V Howard · Medstar Health Research Institute · R01 · FY2015 · HL

Adiponectin and CTRP9 signaling in muscle and liver

$707,419
Harvey F Lodish · Whitehead Institute For Biomedical Res · R01 · FY2012 · DK

Targeting Nonalcoholic Fatty Liver Disease during the reproductive period to improve women's health outcomes

$707,389
Tatyana Kushner · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · DK

Impact and Utilization of Scalable Functional Assays in Alagille Syndrome

$707,330
Melissa Ann Gilbert · Children'S Hosp Of Philadelphia · R01 · FY2025 · DK

Role of Tim Family Genes in Asthma and Allergic Diseases

$707,268
Stanford University · P01 · FY2003 · AI

Plant-derived vaccines against hepatitis C Cooperative *

$707,140
Charles Joel Arntzen · Arizona State University-Tempe Campus · U19 · FY2007 · AI

Delivery of Addiction Treatment for Medicaid Enrollees with Serious Injection-Related Infections

$707,109
Shashi Kapadia · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · DA

Changes in Coronary Noncalcified Volume in Relation to Changes in Cocaine Use

$707,105
Shenghan Lai · Johns Hopkins University · R01 · FY2013 · DA

Dysregulated neutrophil subpopulations as a driving mechanism of liver and gastrointestinal disease in HIV-1-infected individuals

$707,087
Zdenek Hel · University Of Alabama At Birmingham · R01 · FY2023 · DK

A Randomized Trial to Test the Efficacy of a Partner Navigation Intervention for HCV Treatment among Young Adult People who Inject Drugs

$707,087
Meghan D Morris · University Of California, San Francisco · R01 · FY2023 · DA

Molecular Mechanisms Of Hepatitis B Viral Pathogenesis And Persistence

$707,036
T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2014 · DK

Molecular Approaches To Antiviral and Vaccine Development For Hepatitis C

$707,036
T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2014 · DK

Mechanisms of Therapy and Model Development in Hepatitis C and Liver Diseases

$707,036
T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2014 · DK

KLF14 and Atherosclerosis

$706,887
Yuqing E Chen · University Of Michigan At Ann Arbor · R01 · FY2020 · HL

KLF14 and Atherosclerosis

$706,887
Yuqing E Chen · University Of Michigan At Ann Arbor · R01 · FY2019 · HL

Optimization of Substituted Phenoxyalkyl Pyridinium Oximes as Therapies for Organophosphate Poisoning

$706,875
Janice E. Chambers · Mississippi State University · U01 · FY2021 · NS

Defining targets of protective immunity to vivax malaria using human monoclonal antibodies

$706,868
Christopher L King · Case Western Reserve University · R01 · FY2023 · AI

Genomewide Association Study of Lipid Response to Fenofibrate and Dietary Fat

$706,804
Donna K. Arnett · University Of Kentucky · R01 · FY2017 · HL

HCV Disease Management in HIV-HCV Coinfected IDUs

$706,777
Mark Sebastian Sulkowski · Johns Hopkins University · R01 · FY2017 · DA

Defining targets of protective immunity to vivax malaria using human monoclonal antibodies

$706,742
Christopher L King · Case Western Reserve University · R01 · FY2022 · AI

Determinants of AAV Tropism

$706,729
Aravind Asokan · Duke University · R01 · FY2025 · HL

Inflammatory response to sleep apnea in obese subjects

$706,674
Julio Alonso Chirinos Medina · University Of Pennsylvania · R01 · FY2009 · HL